Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Astrazeneca Plc (NY: AZN)
42.77 USD  -0.13 (-0.30%)
Official Closing Price  /  Updated: 6:30 PM EDT, Sep 13, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 3,658,800
Open 42.87
Bid (Size) 42.71 (4)
Ask (Size) 47.00 (7)
Prev. Close 42.90
Today's Range 42.72 - 43.12
52wk Range 35.30 - 45.69
Shares Outstanding 2,533,294,824
Dividend Yield 3.20%
Performance
YTD
+13.15%
+13.15%
1 Month
-3.54%
-3.54%
3 Month
+6.98%
+6.98%
6 Month
+0.45%
+0.45%
1 Year
+13.87%
+13.87%
Top News
More News
IMFINZI Is First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer
AstraZeneca today presented detailed results from the Phase III CASPIAN trial, showing IMFINZI® (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated... Read More
from Business Wire News Releases
Theragnostics Signs Agreement with AstraZeneca
- Enables development of first-in-class molecular radiotherapy based on PARP inhibitor Read More
from PR Newswire
More News
Read More
UPDATE 2-Biogen scraps two late-stage trials for Alzheimer's treatment
category companyNews
from Reuters: Company News
Week in Review: Hansoh Signs $1.5 Billion Cross-Border Deal for AI-Drug Discovery with Atomwise
from ChinaBio® Today
UPDATE 1-Biogen scraps two late-stage Alzheimer's trials
category companyNews
from Reuters: Company News
Week In Review: Hansoh Signs $1.5 Billion Cross-Border Deal For AI-Drug Discovery With Atomwise
category Pharma/Biotech , Stocks / Equities
from Blogs - TalkMarkets
CORRECTED-AstraZeneca's Imfinzi prolongs survival in aggressive lung cancer
category companyNews
from Reuters: Company News
Neurotrope shares crash after Alzheimer's drug fails in trial
category companyNews
from Reuters: Company News
AstraZeneca's Imfinzi prolongs survival in aggressive lung cancer
category companyNews
from Reuters: Company News
AstraZeneca, Wuxi City Partner to Open New China Life Science Park
from ChinaBio® Today
Drugmakers file second court challenge to Canada's new drug price rules
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.